Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Government funding 4.5 millions in

<< Previous

Bullboard Posts

Next >>

Comment by Golddetectoron Feb 16, 2022 11:32am

75 Views

Post# 34433919

RE:RE:RE:RE:RE:RE:Government funding 4.5 millions in

Yap very strong statement from the minister. As I said strong validation to Tbp work

Savage97 wrote:
Tetra's strong growth potential in the Life Sciences sector is recognized by the Government of Quebec.

"Our support of Tetra Bio-Pharma will lead to the development of medication to treat acute respiratory distress syndrome, such as in severe cases of COVID-19. Our government will always be there to support potentially life-changing initiatives for the population, especially when they contribute to the vitality of the Qubec life-sciences sector and Quebec'sreputation in the field of biotechnology," said Pierre Fitzgibbon, Minister of the Economy and Innovation and Minister Responsible for Regional Economic Development.

"Tetra has been the subject of several diligent reviews by the MEI and IQ, which validates our scientific, financial, and commercial approach. In addition, the MEI/IQ adheres to the strategic vision of the team of scientists and managers behind the development of our products. I know that investors have been waiting for this announcement for a long time and I am delighted that it has finally arrived" says Steeve Nron, Chief Commercial Officer of Tetra Bio-Pharma.